Emab treatment was found to induce a partial reduction of circulating B cells in SLE patients affecting primarily CD27– cells [54], a phenomenon that later led to an exploration of the in-vitro effects of Emab on the expression of the adhesion molecules CD62L, β7 integrin, and β1 integrin and on B-cell migration toward CXCL12 [41]. This evidence concerns the gene CD27 and systemic lupus erythematosus.